

Generalized Anxiety Disorder - Pipeline Insight, 2021

<https://marketpublishers.com/r/GBE3E852379EEN.html>

Date: September 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: GBE3E852379EEN

Abstracts

This report can be delivered to the clients within 48-72 hours

DelveInsight's, "Generalized Anxiety Disorder – Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Generalized Anxiety Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Generalized Anxiety Disorder Understanding

Generalized Anxiety Disorder: Overview

Generalized anxiety disorder (or GAD) is marked by excessive, exaggerated anxiety and worry about everyday life events for no obvious reason. People with symptoms of generalized anxiety disorder tend to always expect disaster and can't stop worrying about health, money, family, work, or school. GAD is diagnosed when a person finds it difficult to control worry on more days than not for at least six months and has three or more symptoms. This differentiates GAD from worry that may be specific to a set stressor or for a more limited period of time. Generalized anxiety disorder symptoms include: Feeling restless, wound-up, or on-edge, being easily fatigued, having difficulty concentrating; mind going blank, being irritable, and having muscle tension, difficulty controlling feelings of worry. Experts don't know the exact causes of generalized

anxiety disorder. Several things -- including genetics, brain chemistry, and environmental stresses -- appear to contribute to its development. Cognitive behavioral therapy, helps to limit distorted thinking by looking at worries more realistically. Medications aren't a cure, but they can help ease symptoms. The drugs most often used to treat GAD in the short term (since they can be addictive, are sedating, and can interfere with memory and attention) are from a group of drugs called benzodiazepines. These medications are sometimes called "sedative-hypnotics" or 'minor tranquilizers' because they can temporarily remove intense feelings of sudden (acute) anxiety. They work by curbing the physical symptoms of anxiety, such as muscle tension and restlessness. Common benzodiazepines include alprazolam (Xanax), chlordiazepoxide Hcl (Librium), diazepam (Valium), and lorazepam (Ativan).

'Generalized Anxiety Disorder - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Generalized Anxiety Disorder pipeline landscape is provided which includes the disease overview and Generalized Anxiety Disorder treatment guidelines. The assessment part of the report embraces, in depth Generalized Anxiety Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Generalized Anxiety Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Generalized Anxiety Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Generalized Anxiety Disorder.

Generalized Anxiety Disorder Emerging Drugs Chapters

This segment of the Generalized Anxiety Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Generalized Anxiety Disorder Emerging Drugs

Cannabidiol: Tilray

Tilray, a leading global cannabis-lifestyle and consumer packaged goods company is conducting Phase III clinical trial to treat generalized anxiety disorders. A Phase III study aims to evaluate the efficacy of daily Cannabidiol (CBD) Oil Capsules in treating symptoms of DSM-5 anxiety disorders, using a two-arm, 8-week randomized, placebo-controlled trial in adults aged 21-65 years. The study will also evaluate the relationship between inflammation, anxiety and CBD using biological markers as well as examine the neuro-cognitive effects of CBD treatment.

CD-008-0045: ChemRar Research and Development Institute, LLC

AVN-101 is a novel drug candidate designed as a multi-targeted therapy for the treatment of cognitive, neurodegenerative, and anxiety disorders, which affect millions of people worldwide. Avineuro Project from ChemRar Research Institute is conducting the multicenter, randomized, double-blind, placebo-controlled Phase III pilot study to demonstrate the efficacy, safety, and dosage of innovative drug AVN-101, (CD-008-0045), in patients with the generalized anxiety disorder (GAD). AVN 101, a first-in-class, small-molecule, serotonin 5-HT₆ receptor antagonist, for use as a cognitive enhancer for the treatment of GAD.

Further product details are provided in the report.

Generalized Anxiety Disorder: Therapeutic Assessment

This segment of the report provides insights about the different Generalized Anxiety Disorder drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Generalized Anxiety Disorder

There are approx. 10+ key companies which are developing the therapies for Generalized Anxiety Disorder. The companies which have their Generalized Anxiety

Disorder drug candidates in the most advanced stage, i.e. Phase III include, Tilray.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Generalized Anxiety Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Generalized Anxiety Disorder: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Generalized Anxiety Disorder therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Generalized Anxiety Disorder drugs.

Generalized Anxiety Disorder Report Insights

Generalized Anxiety Disorder Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Generalized Anxiety Disorder Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Generalized Anxiety Disorder drugs?

How many Generalized Anxiety Disorder drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Generalized Anxiety Disorder?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Generalized Anxiety Disorder therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Generalized Anxiety Disorder and their status?

What are the key designations that have been granted to the emerging drugs?

Contents

- Introduction
- Executive Summary
- Generalized Anxiety Disorder: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Late Stage Products (Phase III)
 - Comparative Analysis
- Cannabidiol: Tilray
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.
- Mid Stage Products (Phase II)
 - Comparative Analysis
- Cariprazine: Allergan
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.
- Preclinical stage products
 - Comparative Analysis
- PSY-05: PSY Therapeutics
 - Product Description
 - Research and Development
 - Product Development Activities

Drug profiles in the detailed report.

Inactive Products

Comparative Analysis

Generalized Anxiety Disorder Key Companies

Generalized Anxiety Disorder Key Products

Generalized Anxiety Disorder- Unmet Needs

Generalized Anxiety Disorder- Market Drivers and Barriers

Generalized Anxiety Disorder- Future Perspectives and Conclusion

Generalized Anxiety Disorder Analyst Views

Generalized Anxiety Disorder Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Generalized Anxiety Disorder
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Generalized Anxiety Disorder
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Generalized Anxiety Disorder - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/GBE3E852379EEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GBE3E852379EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970